01:00 - Source: CNN
Cancer: The facts

Story highlights

Could we someday be vaccinated against deadly tumors?

Here's a look at the past, present and future of cancer vaccine research

CNN —  

The thought of a vaccine might conjure up memories of that flu shot you get each year, or taking your kids to get their immunizations against polio or measles. Cancer rarely comes to mind when most people think of vaccines, but that appears to be changing.

Over several decades, cancer vaccines have emerged as a form of immunotherapy, a treatment approach that stimulates or restores the body’s own immune system to either help prevent cancer from developing or help treat an existing cancer.

The HPV vaccine is among the best-known cancer preventive vaccines. It helps prevent human papillomavirus infections. Certain HPV infections are associated with cervix, vagina, vulva, penis, anus, rectum, and head and neck cancers.

As for cancer treatment vaccines, the first to be approved by the Food and Drug Administration in the United States is Provenge or sipuleucel-T, which harnesses a patient’s own immune system to attack cancer cells. The vaccine is approved for use in some men with prostate cancer.

“Whether used for prevention of infectious diseases or for prevention and treatment of cancer, vaccines work by similar mechanisms: They teach the immune system how to recognize the infectious pathogen or the cancer cell as something foreign that needs to be eliminated,” said Dr. Dmitriy Zamarin, a cancer immunologist at Memorial Sloan Kettering Cancer Center in New York who researches vaccines.

“In the case of cancer, various vaccine strategies teach the immune system to recognize a protein, also known as antigen, or a part of a protein that is present on the surface of cancer cells but not normal cells,” he said. “By targeting these proteins, the immune system can specifically eliminate cancer cells while leaving normal cells intact.”

Here’s a look at the past successes and failures of cancer vaccine research, and where the future of research is heading.

19th century: The ‘father of immunotherapy’

In the 1890s, the man who is considered “the father of cancer immunotherapy” noticed something in his cancer patients that would forever impact the course of cancer research.

Dr. William Coley observed that feverish infections in some of his cancer patients, such as bacterial skin infections, were sometimes associated with the cancer regressing.

To test this, Coley concocted a mixture of bacteria. He used a cocktail called Coley’s toxins to create infections in his cancer patients in an effort to trigger their immune systems to attack not only those bacterial infections but other parts of the body that appeared foreign, such as a malignant tumor.

Coley described these cases in a study published in the American Journal of the Medical Sciences in May 1893. One was a 35-year-old Italian man diagnosed with sarcoma of the neck and tonsil.

In the study, Coley detailed how the man’s tumor was injected with streptococcal bacteria that caused a skin infection called erysipelas.

The patient’s temperature rose to 105 degrees Fahrenheit as the skin infection appeared on his neck and gradually extended over his face and head, Coley wrote.

Then, “the tumor of the neck began to break down on the second day, and discharged until the end of the attack. The discharge was not pus, but resembled the caseous material of the tubercular gland,” he wrote. “At the end of two weeks the tumor of the neck had disappeared.”

Meanwhile, the patient’s tonsil tumor appeared smaller, but the reduction in size was not as significant, Coley noted.

Despite that case and others, Coley’s toxins were not widely accepted as a possible cancer treatment option for years to come.

1920s-’30s: A turn of opinions

“Basically, no one understood the mechanism,” said Jill O’Donnell-Tormey, chief executive officer and director of scientific affairs of the Cancer Research Institute in New York.

In other words, no one knew exactly how Coley’s toxins were related to a reduction in tumor growth. Making matters worse, the toxins were a “crude” mixture of bacteria, O’Donnell-Tormey said.

“There was no standardization, so every batch was somewhat different, and some were more potent than others, so you got a variability of response,” she said.

“Some patients responded, and some didn’t, and no one understood why … and then radiation was discovered,” she said. “So radiation became kind of the new treatment du jour as a way to treat cancer. It produced more reliable results than Coley’s toxins could, and that contributed to it being more widely adopted as a cancer treatment.”

By 1920, Coley’s research received serious resistance from the Bone Sarcoma Registry, whose role was to standardize the diagnosis and treatment of bone cancers. Members of the registry believed that Coley’s toxins were ineffective, dismissing his ideas, according to a paper published in The Iowa Orthopaedic Journal in 2006.

Then, the Journal of the American Medical Association, which had criticized Coley’s work, published an editorial in 1934 suggesting that his immunotherapy approach might warrant further research.

“Although Coley first employed a vaccine of Streptococcus [erysipelas] in inoperable malignant conditions as early as 1893, a satisfactory explanation of the therapeutic mechanism has not yet been advanced,” the editorial began.

It ended with, “Further studies on the effect of powerfully antigenic substances in inoperable malignant conditions or as a postoperative measure in attempting to combat recurrence seem to be indicated in the light of the accumulated evidence.”

1950s-’70s: Repurposing a tuberculosis vaccine

Coley’s daughter, Helen Coley Nauts, founded the Cancer Research Institute in 1953 to revive the research that her father started.

“Helen was convinced that the medical community had dismissed her father’s work prematurely,” O’Donnell-Tormey said.

Around that time, cancer immunologist Dr. Lloyd Old and other researchers began investigating incorporating the tuberculosis vaccine bacille Calmette-Guérin, or BCG, into an experimental cancer treatment approach.

In a study in the journal Nature in 1959, Old and his colleagues describe how the growth of sarcoma tumors transplanted into mice was inhibited if the mice were infected with BCG.

For the study, the mice were either implanted with solid tumors or injected with cancer cells at various intervals after being injected with BCG.

The researchers found that the BCG infection still appeared to protect the mice against tumor growth even if tumors developed 67 days after the mice received the BCG injection.

“The tumors in bacillus Calmette-Guérin infected animals developed normally for the first seven to 10 days and then began decreasing in size after the second week,” the researchers wrote in the study.

BCG has since been developed as an immunotherapy to treat bladder cancer. Once put directly into the bladder through a catheter, BCG can activate the body’s immune system cells and attract them to the bladder, according to the American Cancer Society.

In 1971, Old was appointed the Cancer Research Institute’s medical director, and in the years to come, he and other researchers continued to advance cancer vaccine research with many other studies.

However, some of those studies were not as successful as others.

1980s-2000s: Turning a spotlight on antigens

With vaccines, researchers typically try to stimulate the immune system to attack cancer cells by giving the immune system targets to go after. Those targets, found on the surfaces of cancer cells, are called antigens.

But normal cells in the body also sometimes sport the same antigens as cancer cells. When that happens, the immune system can attack a patient’s own body, not just the cancer, causing the vaccine to fail and even turn deadly.

“The history of cancer vaccines has been riddled with a lot of failures,” O’Donnell-Tormey said, and many of those failures happened in the ‘90s and 2000s.

To address this issue, Old started to examine cancer-specific antigens as part of the Cancer Vaccine Collaborative, a joint research initiative established in 2001 between the Cancer Research Institute and the Ludwig Institute for Cancer Research.

“Many people thought things like vaccines had been tried and failed, and he kept on saying, ‘But they’ve never been tried in the right way,’ ” O’Donnell-Tormey said of Old, who died of prostate cancer at age 78 in 2011.

“I think vaccines are coming back,” she said. “They had a very bad rap for a number of years because there was so much failure, but I think they failed because we didn’t understand the biology enough.”

2010s: The hope and hype

Cancer vaccines made a big comeback when the FDA approved Provenge or sipuleucel-T for treatment of prostate cancer in 2010.

Five years later, scientists in Cuba and the US collaborated to develop a lung cancer vaccine. Their early trials suggested that the treatment could help patients younger than 60 to live, on average, 11 months longer than those who did not receive the vaccination.

In 2016, researchers found that a personalized cancer vaccine created with patients’ own acute leukemia cells may be protective against disease relapse. They published their findings in the journal Science Translational Medicine.

The researchers tested the vaccine in 17 acute myeloid leukemia patients who had received chemotherapy. The vaccination was found to be well-tolerated, and after receiving it, 12 of the patients remained in remission for an average of four years and nine months.

“The majority of cancer vaccines will not be clinically effective on their own. They probably need to be combined with other agents that deal with the immunosuppressive milieu around a tumor, such as checkpoint blockades or another type of treatment,” said O’Donnell-Tormey, who was not involved in that study.

“We’ve learned that every person’s tumor – even if it’s all breast cancer or all colon cancer – all have their own antigens, or the markers that the immune system see that are very personalized to that individual patient,” she added.

Though some studies have shown certain cancer vaccines to be effective, other cancer vaccine trials have not been as successful.

For instance, the company Celldex Therapeutics announced in 2016 that a phase three study of a cancer vaccine candidate for glioblastoma, the aggressive type of brain cancer that Sen. John McCain was diagnosed with last year, was unlikely to “reach statistical significance for overall survival in patients with minimal residual disease.” That study was discontinued.

Though no safety concerns were identified, a separate prostate cancer vaccine candidate failed to improve patient survival in a phase two clinical trial, the company